Literature DB >> 23571772

Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.

I Zineh1, J Woodcock.   

Abstract

The "regulatory paradox" is a tension between aversion to uncertainty and willingness to accept unknowns about a drug before its approval. Finding the right balance may mean the difference between fostering and stifling innovation. Clinical pharmacology applied in the drug development and regulatory contexts can bridge mechanistic reasoning and empiricism to help reconcile the regulatory paradox. Here, we propose that the discipline of clinical pharmacology, in the regulatory setting, is well positioned to build on its past successes in the advancement and acceleration of drug development.

Mesh:

Year:  2013        PMID: 23571772     DOI: 10.1038/clpt.2013.32

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  The risks of risk aversion in drug regulation.

Authors:  Hans-Georg Eichler; Brigitte Bloechl-Daum; Daniel Brasseur; Alasdair Breckenridge; Hubert Leufkens; June Raine; Tomas Salmonson; Christian K Schneider; Guido Rasi
Journal:  Nat Rev Drug Discov       Date:  2013-11-15       Impact factor: 84.694

Review 2.  Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit.

Authors:  Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2015-08       Impact factor: 5.606

Review 3.  Integration of PKPD relationships into benefit-risk analysis.

Authors:  Francesco Bellanti; Rob C van Wijk; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

4.  Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review.

Authors:  Davide Grisafi; Alessandro Ceschi; Gianni Sava; Veronica Avalos Clerici; Francesco Scaglione
Journal:  Eur J Clin Pharmacol       Date:  2018-07-14       Impact factor: 2.953

5.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14

Review 6.  Considerations for Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease.

Authors:  Robert N Schuck; Janet Woodcock; Issam Zineh; Peter Stein; Jonathan Jarow; Robert Temple; Thomas Permutt; Lisa LaVange; Julia A Beaver; Rosane Charlab; Gideon M Blumenthal; Sarah E Dorff; Christopher Leptak; Steven Lemery; Hobart Rogers; Badrul Chowdhury; E David Litwack; Michael Pacanowski
Journal:  Clin Pharmacol Ther       Date:  2018-02-23       Impact factor: 6.875

Review 7.  Implementation of quantitative and systems pharmacology in large pharma.

Authors:  S A G Visser; D P de Alwis; T Kerbusch; J A Stone; S R B Allerheiligen
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-22

8.  The impact of composite AUC estimates on the prediction of systemic exposure in toxicology experiments.

Authors:  Tarjinder Sahota; Meindert Danhof; Oscar Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-04-14       Impact factor: 2.745

9.  Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition.

Authors:  S Zheng; P Gaitonde; M A Andrew; M A Gibbs; L J Lesko; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-01

Review 10.  Leveraging Genomic Factors to Improve Benefit-Risk.

Authors:  R N Schuck; R Charlab; G M Blumenthal
Journal:  Clin Transl Sci       Date:  2017-02-03       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.